CA1202639A - Derives d'aryl-1 aminomethyl-2 cyclopropanes carboxamides (z) et leur preparation - Google Patents
Derives d'aryl-1 aminomethyl-2 cyclopropanes carboxamides (z) et leur preparationInfo
- Publication number
- CA1202639A CA1202639A CA000405651A CA405651A CA1202639A CA 1202639 A CA1202639 A CA 1202639A CA 000405651 A CA000405651 A CA 000405651A CA 405651 A CA405651 A CA 405651A CA 1202639 A CA1202639 A CA 1202639A
- Authority
- CA
- Canada
- Prior art keywords
- hydrochloride
- cyclopropane
- dimethylaminomethyl
- phenyl
- aminomethyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 238000002360 preparation method Methods 0.000 title claims description 22
- 150000003857 carboxamides Chemical class 0.000 title 2
- 150000001942 cyclopropanes Chemical class 0.000 title 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims abstract description 20
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- 229910052757 nitrogen Inorganic materials 0.000 claims abstract description 12
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims abstract description 11
- 125000005843 halogen group Chemical group 0.000 claims abstract description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims abstract description 8
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims abstract description 7
- 150000003839 salts Chemical class 0.000 claims abstract description 7
- 125000003545 alkoxy group Chemical group 0.000 claims abstract description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims abstract description 5
- 239000011707 mineral Substances 0.000 claims abstract description 5
- 125000003118 aryl group Chemical group 0.000 claims abstract description 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims abstract description 4
- 125000005842 heteroatom Chemical group 0.000 claims abstract description 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims abstract description 4
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 4
- 239000001301 oxygen Substances 0.000 claims abstract description 4
- 125000002877 alkyl aryl group Chemical group 0.000 claims abstract 3
- 239000001257 hydrogen Substances 0.000 claims abstract 3
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 3
- 150000007522 mineralic acids Chemical class 0.000 claims abstract 3
- 150000007524 organic acids Chemical class 0.000 claims abstract 3
- 235000005985 organic acids Nutrition 0.000 claims abstract 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 43
- LVZWSLJZHVFIQJ-UHFFFAOYSA-N Cyclopropane Chemical compound C1CC1 LVZWSLJZHVFIQJ-UHFFFAOYSA-N 0.000 claims description 23
- 238000000034 method Methods 0.000 claims description 21
- -1 hydrochloride 1-phenyl-1-chlorocarbonyl-2-dimethylaminomethyl cyclo-propane Chemical compound 0.000 claims description 15
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 12
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 claims description 12
- 125000004429 atom Chemical group 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 229910021529 ammonia Inorganic materials 0.000 claims description 7
- 239000000126 substance Substances 0.000 claims description 6
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims description 5
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims description 5
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 claims description 3
- 239000011976 maleic acid Substances 0.000 claims description 3
- 150000001412 amines Chemical class 0.000 claims description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 claims description 2
- 229950011148 cyclopropane Drugs 0.000 claims 6
- 238000001311 chemical methods and process Methods 0.000 claims 3
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 claims 2
- HQTOGRJJEXEVDY-UHFFFAOYSA-N 2-(3,5-dimethoxy-4-propoxyphenyl)ethanamine;hydrochloride Chemical compound Cl.CCCOC1=C(OC)C=C(CCN)C=C1OC HQTOGRJJEXEVDY-UHFFFAOYSA-N 0.000 claims 1
- MJVGQMVWULRQRI-UHFFFAOYSA-N 2-(aminomethyl)-n,n-diethylcyclopropane-1-carboxamide Chemical compound CCN(CC)C(=O)C1CC1CN MJVGQMVWULRQRI-UHFFFAOYSA-N 0.000 claims 1
- KGVHCQKNBHYQOK-UHFFFAOYSA-N 2-[(dimethylamino)methyl]-n,n-dimethyl-1-phenylcyclopropane-1-carboxamide Chemical compound CN(C)CC1CC1(C(=O)N(C)C)C1=CC=CC=C1 KGVHCQKNBHYQOK-UHFFFAOYSA-N 0.000 claims 1
- WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 claims 1
- 238000011282 treatment Methods 0.000 abstract description 6
- 210000003169 central nervous system Anatomy 0.000 abstract description 2
- 229910052801 chlorine Inorganic materials 0.000 abstract description 2
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 2
- 125000001309 chloro group Chemical group Cl* 0.000 abstract 1
- 239000000047 product Substances 0.000 description 19
- 239000000460 chlorine Substances 0.000 description 14
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 12
- 239000013078 crystal Substances 0.000 description 11
- 238000002844 melting Methods 0.000 description 11
- 230000008018 melting Effects 0.000 description 11
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 10
- IJKVHSBPTUYDLN-UHFFFAOYSA-N dihydroxy(oxo)silane Chemical compound O[Si](O)=O IJKVHSBPTUYDLN-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 230000003301 hydrolyzing effect Effects 0.000 description 9
- 229910052740 iodine Inorganic materials 0.000 description 9
- 239000011630 iodine Substances 0.000 description 9
- 238000002329 infrared spectrum Methods 0.000 description 7
- MHLMRBVCMNDOCW-UHFFFAOYSA-N acetic acid;butan-1-ol;hydrate Chemical compound O.CC(O)=O.CCCCO MHLMRBVCMNDOCW-UHFFFAOYSA-N 0.000 description 6
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 description 6
- 150000004820 halides Chemical class 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- DQVRGSIXUGZCOV-UHFFFAOYSA-N 1-cyclopropyl-n,n-dimethylmethanamine Chemical compound CN(C)CC1CC1 DQVRGSIXUGZCOV-UHFFFAOYSA-N 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 150000007513 acids Chemical class 0.000 description 3
- OJHAHQJRQIOCFK-UHFFFAOYSA-N azane;chloroform;methanol Chemical compound N.OC.ClC(Cl)Cl OJHAHQJRQIOCFK-UHFFFAOYSA-N 0.000 description 3
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 208000020401 Depressive disease Diseases 0.000 description 2
- BHHGXPLMPWCGHP-UHFFFAOYSA-N Phenethylamine Chemical compound NCCC1=CC=CC=C1 BHHGXPLMPWCGHP-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000001413 amino acids Chemical class 0.000 description 2
- 230000001430 anti-depressive effect Effects 0.000 description 2
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 208000015114 central nervous system disease Diseases 0.000 description 2
- JFYKIEHOOZWARC-UHFFFAOYSA-N cyclopropanecarbohydrazide Chemical class NNC(=O)C1CC1 JFYKIEHOOZWARC-UHFFFAOYSA-N 0.000 description 2
- IGSKHXTUVXSOMB-UHFFFAOYSA-N cyclopropylmethanamine Chemical compound NCC1CC1 IGSKHXTUVXSOMB-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 description 2
- MAGVJLLHDZWQFM-UHFFFAOYSA-N n-chloro-n-methylmethanamine Chemical compound CN(C)Cl MAGVJLLHDZWQFM-UHFFFAOYSA-N 0.000 description 2
- 208000015238 neurotic disease Diseases 0.000 description 2
- 238000003756 stirring Methods 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- YMVFJGSXZNNUDW-UHFFFAOYSA-N (4-chlorophenyl)methanamine Chemical compound NCC1=CC=C(Cl)C=C1 YMVFJGSXZNNUDW-UHFFFAOYSA-N 0.000 description 1
- RNSGBYUFHBXKPU-UHFFFAOYSA-N 1-chloropyrrolidine Chemical compound ClN1CCCC1 RNSGBYUFHBXKPU-UHFFFAOYSA-N 0.000 description 1
- QTXYPJCMJSHCKH-UHFFFAOYSA-N 2-(hydroxymethyl)-2-phenylcyclopropane-1-carboxylic acid Chemical compound C1(=CC=CC=C1)C1(C(C1)C(=O)O)CO QTXYPJCMJSHCKH-UHFFFAOYSA-N 0.000 description 1
- 125000004182 2-chlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(*)C([H])=C1[H] 0.000 description 1
- XLIGZSVTKYWLQY-UHFFFAOYSA-N 2-phenylethyl hypochlorite Chemical compound ClOCCC1=CC=CC=C1 XLIGZSVTKYWLQY-UHFFFAOYSA-N 0.000 description 1
- ZSUIVGFKRHPJPP-UHFFFAOYSA-N CN(C)CC(C1)C1(CC(C=C1)=CC=C1Cl)C1=CC=CC=C1 Chemical compound CN(C)CC(C1)C1(CC(C=C1)=CC=C1Cl)C1=CC=CC=C1 ZSUIVGFKRHPJPP-UHFFFAOYSA-N 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 241000065675 Cyclops Species 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- MUQNGPZZQDCDFT-JNQJZLCISA-N Halcinonide Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H]3OC(C)(C)O[C@@]3(C(=O)CCl)[C@@]1(C)C[C@@H]2O MUQNGPZZQDCDFT-JNQJZLCISA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- NGVRHZUQJPIGKO-UHFFFAOYSA-N N,N,2-trimethylcyclopropan-1-amine Chemical compound CN(C1C(C1)C)C NGVRHZUQJPIGKO-UHFFFAOYSA-N 0.000 description 1
- DVQLGAFYVKJEDE-UHFFFAOYSA-N N,N-dimethylcyclopropanecarboxamide Chemical compound CN(C)C(=O)C1CC1 DVQLGAFYVKJEDE-UHFFFAOYSA-N 0.000 description 1
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 1
- BLGXFZZNTVWLAY-CCZXDCJGSA-N Yohimbine Natural products C1=CC=C2C(CCN3C[C@@H]4CC[C@@H](O)[C@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-CCZXDCJGSA-N 0.000 description 1
- 208000012826 adjustment disease Diseases 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- BLGXFZZNTVWLAY-UHFFFAOYSA-N beta-Yohimbin Natural products C1=CC=C2C(CCN3CC4CCC(O)C(C4CC33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- NEHMKBQYUWJMIP-UHFFFAOYSA-N chloromethane Chemical compound ClC NEHMKBQYUWJMIP-UHFFFAOYSA-N 0.000 description 1
- AIMMVWOEOZMVMS-UHFFFAOYSA-N cyclopropanecarboxamide Chemical compound NC(=O)C1CC1 AIMMVWOEOZMVMS-UHFFFAOYSA-N 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 208000024732 dysthymic disease Diseases 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 229940028332 halog Drugs 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 231100000053 low toxicity Toxicity 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- FMZGKCMVTMNFIH-UHFFFAOYSA-N n-(2-phenylethyl)cyclopropanecarboxamide Chemical compound C1CC1C(=O)NCCC1=CC=CC=C1 FMZGKCMVTMNFIH-UHFFFAOYSA-N 0.000 description 1
- TYDFLVGVWMSQAC-UHFFFAOYSA-N n-chloro-n-ethylethanamine Chemical compound CCN(Cl)CC TYDFLVGVWMSQAC-UHFFFAOYSA-N 0.000 description 1
- QXJIABOUHLYVHP-UHFFFAOYSA-N n-chloromethanamine Chemical compound CNCl QXJIABOUHLYVHP-UHFFFAOYSA-N 0.000 description 1
- 208000025319 neurotic depression Diseases 0.000 description 1
- 125000000636 p-nitrophenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)[N+]([O-])=O 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000010189 synthetic method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- BLGXFZZNTVWLAY-SCYLSFHTSA-N yohimbine Chemical compound C1=CC=C2C(CCN3C[C@@H]4CC[C@H](O)[C@@H]([C@H]4C[C@H]33)C(=O)OC)=C3NC2=C1 BLGXFZZNTVWLAY-SCYLSFHTSA-N 0.000 description 1
- 229960000317 yohimbine Drugs 0.000 description 1
- AADVZSXPNRLYLV-UHFFFAOYSA-N yohimbine carboxylic acid Natural products C1=CC=C2C(CCN3CC4CCC(C(C4CC33)C(O)=O)O)=C3NC2=C1 AADVZSXPNRLYLV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
- C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
- C07D295/182—Radicals derived from carboxylic acids
- C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/26—Psychostimulants, e.g. nicotine, cocaine
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychiatry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Pain & Pain Management (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR8112312 | 1981-06-23 | ||
| FR8112312A FR2508035A1 (fr) | 1981-06-23 | 1981-06-23 | Derives d'aryl-1-aminomethyl-2 cyclopropanes carboxamides (z), leur preparation et leur application en tant que medicaments utiles dans le traitement des troubles du systeme nerveux central |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA1202639A true CA1202639A (fr) | 1986-04-01 |
Family
ID=9259785
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA000405651A Expired CA1202639A (fr) | 1981-06-23 | 1982-06-22 | Derives d'aryl-1 aminomethyl-2 cyclopropanes carboxamides (z) et leur preparation |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4478836A (OSRAM) |
| EP (1) | EP0068999B1 (OSRAM) |
| JP (1) | JPS584752A (OSRAM) |
| AT (1) | ATE13422T1 (OSRAM) |
| AU (1) | AU550774B2 (OSRAM) |
| CA (1) | CA1202639A (OSRAM) |
| DE (1) | DE3263734D1 (OSRAM) |
| ES (1) | ES512842A0 (OSRAM) |
| FR (1) | FR2508035A1 (OSRAM) |
| LU (1) | LU90410I2 (OSRAM) |
| ZA (1) | ZA824453B (OSRAM) |
Families Citing this family (70)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2581060B1 (fr) * | 1985-04-25 | 1988-07-01 | Pf Medicament | Procede industriel d'obtention du midalcipran |
| FR2581059B1 (fr) * | 1985-04-25 | 1988-04-22 | Pf Medicament | Procede de preparation du chlorhydrate de phenyl-1 diethyl amino carbonyl-1 aminomethyl-2 cyclopropane (z) |
| WO1995022521A1 (en) * | 1994-02-22 | 1995-08-24 | Asahi Kasei Kogyo Kabushiki Kaisha | Aminoalkylcyclopropane derivative |
| CA2134038C (en) * | 1994-06-16 | 1997-06-03 | David Taiwai Wong | Potentiation of drug response |
| EP0714663A3 (en) | 1994-11-28 | 1997-01-15 | Lilly Co Eli | Potentiation of drug responses by serotonin 1A receptor antagonists |
| DE69607904T2 (de) * | 1995-08-16 | 2000-10-05 | Eli Lilly And Co., Indianapolis | Potenzierung von Serotonin-Wirkstoffresponz |
| FR2752732B1 (fr) * | 1996-08-28 | 1998-11-20 | Pf Medicament | Forme galenique a liberation prolongee de milnacipran |
| AU2002342045C1 (en) * | 2001-10-12 | 2009-07-30 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl vasopressin Vla antagonists |
| US20040034101A1 (en) * | 2001-11-05 | 2004-02-19 | Cypress Bioscience, Inc. | Treatment and prevention of depression secondary to pain (DSP) |
| US6602911B2 (en) * | 2001-11-05 | 2003-08-05 | Cypress Bioscience, Inc. | Methods of treating fibromyalgia |
| US6635675B2 (en) | 2001-11-05 | 2003-10-21 | Cypress Bioscience, Inc. | Method of treating chronic fatigue syndrome |
| MXPA04011529A (es) * | 2002-04-24 | 2005-08-15 | Cypress Bioscience Inc | Prevencion y tratamiento de trastornos somaticos funcionales, incluyendo trastornos relacionados con la tension. |
| CA2503381A1 (en) * | 2002-10-25 | 2004-05-13 | Collegium Pharmaceutical, Inc. | Stereoisomers of p-hydroxy-milnacipran, and methods of use thereof |
| FR2851163B1 (fr) | 2003-02-14 | 2007-04-27 | Utilisation de l'enantiomere dextrogyre du milnacipran pour la preparation d'un medicament | |
| WO2004075886A1 (fr) * | 2003-02-14 | 2004-09-10 | Pierre Fabre Medicament | Utilisation de l’enantiomere (1s, 2r) du milnacipran pour la preparation d’un medicament |
| MXPA05011225A (es) * | 2003-04-18 | 2005-12-14 | Pharmacia & Upjohn Co Llc | Politerapias. |
| CA2535646C (en) | 2003-08-15 | 2010-08-10 | H. Lundbeck A/S | Cyclopropyl derivatives as nk3 receptor antagonists |
| KR20060066721A (ko) * | 2003-08-15 | 2006-06-16 | 하. 룬트벡 아크티에 셀스카브 | Ｎｋ3 수용체 길항제로서의 시클로프로필 유도체 |
| EP2343073A3 (en) | 2003-12-11 | 2011-10-12 | Sepracor Inc. | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression |
| CA2567249A1 (en) * | 2004-04-19 | 2006-10-05 | Jds Pharmaceuticals, Llc | Lithium combinations, and uses related thereto |
| JP4418717B2 (ja) * | 2004-06-24 | 2010-02-24 | 住友化学株式会社 | （ｚ）−１−フェニル−１−ジエチルアミノカルボニル−２−アミノメチルシクロプロパン塩酸塩の製造方法 |
| CA2601709C (en) | 2005-03-22 | 2017-02-14 | Azevan Pharmaceuticals, Inc. | Beta-lactamylalkanoic acids |
| MX2007012936A (es) * | 2005-04-22 | 2008-01-11 | Wyeth Corp | Derivados de dihidrobenzofurano y usos de los mismos. |
| AU2006239922A1 (en) * | 2005-04-22 | 2006-11-02 | Wyeth | Benzofuranyl alkanamine derivatives and uses thereof as 5-HT2c agonists |
| EP1871755A1 (en) * | 2005-04-22 | 2008-01-02 | Wyeth | Dihydrobenzofuran derivatives and uses thereof |
| CA2611724C (en) * | 2005-06-10 | 2014-07-29 | Pierre Fabre Medicament S.A. | Stabilized milnacipran formulation |
| CA2614289A1 (en) * | 2005-07-08 | 2007-01-18 | Braincells, Inc. | Methods for identifying agents and conditions that modulate neurogenesis |
| AU2006270039B2 (en) * | 2005-07-19 | 2013-07-04 | Azevan Pharmaceuticals, Inc. | Beta-lactamyl phenylalanine, cysteine, and serine vasopressin antagonists |
| WO2007025144A1 (en) * | 2005-08-24 | 2007-03-01 | University Of Illinois - Chicago | 5-ht2c receptor agonists as anorectic agents |
| US7994220B2 (en) * | 2005-09-28 | 2011-08-09 | Cypress Bioscience, Inc. | Milnacipran for the long-term treatment of fibromyalgia syndrome |
| WO2007047978A2 (en) | 2005-10-21 | 2007-04-26 | Braincells, Inc. | Modulation of neurogenesis by pde inhibition |
| JP2009513672A (ja) | 2005-10-31 | 2009-04-02 | ブレインセルス，インコーポレイティド | 神経発生のｇａｂａ受容体媒介調節 |
| WO2007086493A1 (ja) * | 2006-01-27 | 2007-08-02 | Asahi Kasei Pharma Corporation | 経鼻投与用薬剤 |
| US20080319083A1 (en) * | 2006-01-27 | 2008-12-25 | Asahi Kasei Pharma Corporation | Medicine for transnasal administration |
| FR2912057B1 (fr) * | 2007-02-07 | 2009-04-17 | Sanofi Aventis Sa | Composition pharmaceutique contenant en association le saredutant et un inhibiteur selectif de la recapture de la serotonine ou un inhibiteur de la recapture de la serotonine/norepinephrine |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| US20070225279A1 (en) * | 2006-03-24 | 2007-09-27 | Wyeth | Therapeutic combinations for the treatment of depression |
| MX2008014320A (es) | 2006-05-09 | 2009-03-25 | Braincells Inc | Neurogenesis mediada por el receptor de 5-hidroxitriptamina. |
| EP2377531A2 (en) | 2006-05-09 | 2011-10-19 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| US7858611B2 (en) * | 2006-05-09 | 2010-12-28 | Braincells Inc. | Neurogenesis by modulating angiotensin |
| TW200817003A (en) * | 2006-07-31 | 2008-04-16 | Sanofi Aventis | Pharmaceutical composition comprising, in combination, saredutant and a selective serotonin peuptake inhibitor or a serotonin/norepinephrine reuptake inhibitor |
| US7998971B2 (en) | 2006-09-08 | 2011-08-16 | Braincells Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100016274A1 (en) * | 2006-09-14 | 2010-01-21 | Koppel Gary A | Beta-lactam cannabinoid receptor modulators |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| WO2008083204A2 (en) * | 2006-12-28 | 2008-07-10 | Braincells, Inc. | Modulation of neurogenesis by melatoninergic ligands |
| WO2008086483A2 (en) * | 2007-01-11 | 2008-07-17 | Braincells, Inc. | Modulation of neurogenesis with use of modafinil |
| US20100145099A1 (en) * | 2007-02-28 | 2010-06-10 | Ranbaxy Laboratories Limited | Novel polymorphic forms of milnacipran hydrochloride |
| WO2009023820A1 (en) * | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Improving the tolerability of a serotonin antagonist and a nsri, a snri or a rima by using them in combination |
| US20090069431A1 (en) * | 2007-09-12 | 2009-03-12 | Protia, Llc | Deuterium-enriched milnacipran |
| US20110034565A1 (en) | 2008-04-18 | 2011-02-10 | University College Dublin, National University Of Ireland, Dublin | Psycho-pharmaceuticals |
| US20100092479A1 (en) * | 2008-08-18 | 2010-04-15 | Combinatorx (Singapore) Pte. Ltd. | Compositions and methods for treatment of viral diseases |
| WO2010036773A1 (en) * | 2008-09-24 | 2010-04-01 | Concert Pharmaceuticals, Inc. | Deuterated l-aryl-2 -aminomethyl cyclopropane carboxyamide derivatives |
| FR2941454B1 (fr) | 2009-01-29 | 2011-04-01 | Pf Medicament | Proced de synthese du (1s,2r)-milnacipran |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| US20100274050A1 (en) * | 2009-04-23 | 2010-10-28 | Glenmark Generics Limited | Solid milnacipran and process for the preparation of the same |
| WO2010129689A1 (en) * | 2009-05-05 | 2010-11-11 | Forest Laboratories Holdings Limited | Milnacipran formulations |
| CA2775091A1 (en) | 2009-08-05 | 2011-02-10 | Lupin Limited | Controlled release pharmaceutical compositions of milnacipran |
| CA2779711C (en) | 2009-11-06 | 2016-11-01 | Forest Laboratories Holding Limited | Novel crystalline forms of (1s,2r)-2-(amino methyl)-n,n-diethyl-1-phenyl cyclopropane carboxamide |
| WO2011092065A1 (en) | 2010-01-29 | 2011-08-04 | Nicox S.A. | Nitric oxide releasing compounds for the treatment of neurophatic pain |
| WO2012003436A1 (en) | 2010-07-01 | 2012-01-05 | Azevan Pharmaceuticals, Inc. | Methods for treating post traumatic stress disorder |
| JP2013536832A (ja) | 2010-08-30 | 2013-09-26 | ルピン・リミテッド | ミルナシプランの制御放出医薬組成物 |
| WO2012059933A1 (en) | 2010-11-03 | 2012-05-10 | Arch Pharmalabs Limited | A new process for preparing optically pure milnacipran and its pharmaceutically acceptable salts. |
| US20140045936A1 (en) | 2011-04-21 | 2014-02-13 | Wake Forest University Health Sciences | Cyclopropyl derivatives and methods of use |
| WO2014009767A1 (en) | 2012-07-07 | 2014-01-16 | Micro Labs Limited | An improved process for the preparation of 1-aryl 2-aminomethyl cyclopropane carboxyamide (z) derivatives, their isomers and salts |
| WO2014203277A2 (en) * | 2013-06-19 | 2014-12-24 | Msn Laboratories Private Limited | Process for the preparation of (1s,2r)-2-(aminomethyl)-n,n-diethyl-1-phenylcyclopropanearboxamide hydrochloride |
| WO2015044962A1 (en) | 2013-09-30 | 2015-04-02 | Cadila Healthcare Limited | Amorphous form of levomilnacipran hydrochloride and hydrates thereof |
| CA2944211C (en) | 2014-03-28 | 2022-10-04 | Azevan Pharmaceuticals, Inc. | Compositions and methods for treating neurodegenerative diseases |
| EP3681871A4 (en) | 2017-09-15 | 2021-05-26 | Azevan Pharmaceuticals, Inc. | COMPOSITIONS AND METHODS FOR THE TREATMENT OF A BRAIN DAMAGE |
| AU2020316013A1 (en) | 2019-07-19 | 2022-02-17 | Arx, Llc | Non-sedating dexmedetomidine treatment regimens |
| US11806334B1 (en) | 2023-01-12 | 2023-11-07 | Bioxcel Therapeutics, Inc. | Non-sedating dexmedetomidine treatment regimens |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA570688A (en) * | 1959-02-17 | E. Speeter Merrill | Antispasmodic substituted amines | |
| CA619080A (en) * | 1961-04-25 | The Upjohn Company | N-SUBSTITUTED-.alpha.-(TERTIARY-AMINOALKYL)-.alpha.-PHENYLACETAMIDES | |
| GB1415541A (en) * | 1972-11-30 | 1975-11-26 | Hexachimie | 1-amino-methyl-2,2-diarylcyclopropanecarboxamide |
-
1981
- 1981-06-23 FR FR8112312A patent/FR2508035A1/fr active Granted
-
1982
- 1982-06-04 ES ES512842A patent/ES512842A0/es active Granted
- 1982-06-21 AT AT82401129T patent/ATE13422T1/de active
- 1982-06-21 EP EP82401129A patent/EP0068999B1/fr not_active Expired
- 1982-06-21 DE DE8282401129T patent/DE3263734D1/de not_active Expired
- 1982-06-22 CA CA000405651A patent/CA1202639A/fr not_active Expired
- 1982-06-22 AU AU85086/82A patent/AU550774B2/en not_active Expired
- 1982-06-22 US US06/390,810 patent/US4478836A/en not_active Expired - Lifetime
- 1982-06-23 ZA ZA824453A patent/ZA824453B/xx unknown
- 1982-06-23 JP JP57109097A patent/JPS584752A/ja active Granted
-
1999
- 1999-06-30 LU LU90410C patent/LU90410I2/fr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JPS584752A (ja) | 1983-01-11 |
| EP0068999A1 (fr) | 1983-01-05 |
| ZA824453B (en) | 1983-04-27 |
| ES8303293A1 (es) | 1983-03-01 |
| JPS6323186B2 (OSRAM) | 1988-05-16 |
| LU90410I2 (fr) | 1999-08-31 |
| ES512842A0 (es) | 1983-03-01 |
| DE3263734D1 (en) | 1985-06-27 |
| US4478836A (en) | 1984-10-23 |
| AU550774B2 (en) | 1986-04-10 |
| ATE13422T1 (de) | 1985-06-15 |
| FR2508035B1 (OSRAM) | 1984-06-29 |
| AU8508682A (en) | 1983-01-06 |
| EP0068999B1 (fr) | 1985-05-22 |
| FR2508035A1 (fr) | 1982-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CA1202639A (fr) | Derives d'aryl-1 aminomethyl-2 cyclopropanes carboxamides (z) et leur preparation | |
| EP0487408B1 (fr) | Dérivés d'oxazolopyridines leurs procédés de préparation et les compositions pharmaceutiques qui les contiennent | |
| CA1167047A (fr) | Benzodioxanne l,4 methoxy-2 propanolamines, leur preparation et leur application en tant que medicaments | |
| EP0000299B1 (fr) | Nouveaux dérivés de benzoyl-2-chloro-4-glycinanilides substitués, leur procédé de préparation et leur application en tant que médicaments. | |
| EP0068998B1 (fr) | Aryl-1 aminométhyl-2 cyclopropanes carboxylates (Z), leur préparation et leur application en tant que médicaments utiles dans le traitement d'algies diverses | |
| EP0237366B1 (fr) | Aminoalcools, leur procédé de préparation et leurs applications, notamment en thérapeutique | |
| MC2135A1 (fr) | Carboxamides aromatiques | |
| EP0015214B1 (fr) | Nouveaux dérivés de benzoyl-2 glycylanilides substitués, leur préparation et leur application en tant que médicaments anxiolytiques | |
| FR2534915A1 (fr) | Nouveaux derives de 2-(phenoxymethyl)-morpholine, utilisation en therapeutique et procede de preparation | |
| CA1141380A (fr) | Derives de benzoyl-2-nitro-4 anilides, leur preparation et leur application en tant que medicaments | |
| FR2643634A1 (fr) | Nouveaux derives benzoxazolinoniques, leurs procedes de preparation et les compositions pharmaceutiques qui les contiennent | |
| EP0426562B1 (fr) | Dérivés de 1-(4-aminophényl)-2-pipéridinopropanone, procédé de préparation et utilisation en thérapeutique | |
| FR2514355A1 (fr) | Derives de biphenyl alcoyl carboxylates, leur procede de preparation et leur utilisation comme medicaments | |
| EP0143016B1 (fr) | Dérivés de 4-(3-alkynyloxy-2-hydroxy-propyl)-piperazin-1-yl-N-phényl acétamide, leur préparation et leur application en thérapeutique | |
| CA1091233A (fr) | Procede de preparation de nouveaux indoles substitues | |
| EP0136945B1 (fr) | Nouveaux composés cinnamoiques, leur procédé de préparation et leur application en thérapeutique | |
| CA1300642C (fr) | Procede de preparation de l'acide eicosatetraynoique-5,8,11,14 | |
| EP0010030B1 (fr) | Nouveaux dérivés d'ortho chloro benzoyl-2 chloro-4 glycylanilide, leur préparation et leur application en tant que médicaments | |
| MC1169A1 (fr) | Composes tricycliques | |
| CA1105053A (fr) | Sulfamido acetyleniques de benzamides utilisables en therapeutique | |
| FR2525214A1 (fr) | Nouveaux derives d'halogeno benzoyl-2 nitro-4 glycylanilides, leur procede de preparation et leur application en therapeutique | |
| EP0039294B1 (fr) | Bis (phénoxyacétates substitués) de N-alkyl-dialcanolamines, procédé d'obtention, et compositions pharmaceutiques les contenant | |
| RU2026070C1 (ru) | 1-(гидроксиметил)-2-гидрокси-2-(4-нитрофенил)-этиламмоний 2-формилфеноксиацетат, обладающий антистрессорной активностью | |
| FR2497202A1 (fr) | Nouveaux derives de tetrahydro-1,2,4-oxadiazin-5-one, leur preparation et compositions pharmaceutiques les contenant | |
| FR2655042A1 (fr) | Nouvelles benzothiazolinones substituees, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MKEX | Expiry |